Mohammad Shahrokh Esfahani
Stanford University
76 Papers
382 Citations
Mohammad Shahrokh Esfahani is an academic researcher from Stanford University. The author has contributed to research in topics: Prior probability & Medicine. The author has an hindex of 18, co-authored 56 publications. Previous affiliations of Mohammad Shahrokh Esfahani include University of Washington & Texas A&M University.
Chat about Author
Papers
Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.
E. J. Moding,Mohammad Shahrokh Esfahani,Cheng Jin,Angela B Hui,Barzin Y. Nabet,Yufei Liu,Jacob J. Chabon,Michael S. Binkley,D. M. Kurtz,Emily G. Hamilton,A. Chaudhuri,Chih Long Liu,Zhe Li,Rene F Bonilla,Alice Jiang,Brianna C Lau,Pablo Ferrer Lopez,Jianzhong He,Yawei Qiao,Luyang Yao,Saumil Gandhi,Zhongxing Liao,Millie Das,Kavitha Ramchandran,Sukhmani K. Padda,Joel W. Neal,Heather A Wakelee,Michael F. Gensheimer,Bill W. Loo,Ruijiang Li,Steven H. Lin,Ash A. Alizadeh,Maximilian Diehn +32 more
2
Sample-based prior probability construction using biological pathway knowledge
Mohammad Shahrokh Esfahani,Edward R. Dougherty +1 more
- 01 Nov 2013
TL;DR: This paper addresses the problem of prior probability construction by proposing a series of optimization paradigms that utilize the incomplete prior information contained in pathways in the special case of a Normal-Wishart prior distribution on the mean and inverse covariance matrix of a Gaussian distribution.
1
Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification
Jurik Mutter,Mohammad Shahrokh Esfahani,Joseph G Schroers-Martin,Stefan Alig,M. P. Hamilton,Brian Sworder,Benoit Tessoulin,J. Boegeholz,Timothy Flerlage,Jamie E. Flerlage,Michael S. Binkley,Takeshi Sugio,Cédric Rossi,Mari Olsen,Chih Long Liu,Steven Le Gouill,David M. Kurtz,Maximilian Diehn,Ash A. Alizadeh +18 more
TL;DR: A novel noninvasive strategy to detect and classify mature B-cell tumors using plasma cfDNA, with special attention to HGBCL-DH-BCL2 and DZsig, and found high correlations between EPIC-Seq signature scores from cfDNA and corresponding circulating tumor VAFs in each histology.
1
Clinical Impact of Somatic Copy Number Alterations in Circulating Tumor DNA from Diverse Lymphoma Subtypes
Michael C. Jin,David M. Kurtz,Mohammad Shahrokh Esfahani,Joanne Soo,Alexander F.M. Craig,Florian Scherer,Henning Stehr,Joseph G Schroers-Martin,Charles D. Bangs,Athena M. Cherry,Yasodha Natkunam,Mark Roschewski,Wyndham H. Wilson,Ulrich Duehrsen,Andreas Hüttmann,Davide Rossi,Gianluca Gaidano,Jason R. Westin,Ranjana H. Advani,Maximilian Diehn,Ash A. Alizadeh +20 more
TL;DR: This strategy not only allows for the noninvasive genotyping of tumor SCNAs, but also provides an orthogonal method for monitoring residual disease from liquid biopsies using next generation sequencing, which could provide an independent method for detecting residual disease in tumors characterized by structural alterations.
1
A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.
Everett J. Moding,Mohammad Shahrokh Esfahani,Barzin Y. Nabet,Yufei Liu,Jacob J. Chabon,Jianzhong He,Yawei Qiao,Ting Xu,Luyang Yao,Saumil Gandhi,Zhongxing X. Liao,Millie Das,Kavitha Ramchandran,Sukhmani K. Padda,Joel W. Neal,Heather A. Wakelee,Billy W. Loo,Steven H. Lin,Ash A. Alizadeh,Maximilian Diehn +19 more
TL;DR: This data indicates that accumulating circulating tumor DNA molecular residual disease after curative intent therapy predicts disease progression in localized lung cancer through pathways related to EMT and “cell reprograming".
1